rheumatology
DAS28-CRP (Disease Activity Score — Rheumatoid Arthritis)
Measures rheumatoid arthritis disease activity using 28 joint counts (tender and swollen), CRP, and patient global assessment. Guides DMARD therapy.
Score interpretation
Remission (DAS28-CRP <2.6)
→ Remission achieved; maintain current DMARD; consider dose tapering
Low disease activity (2.6-3.2)
→ Low activity; continue current therapy; 3-monthly review
Moderate disease activity (3.2-5.1)
→ Moderate activity; consider DMARD escalation or biologic if inadequate response
High disease activity (>5.1)
→ High activity; escalate treatment; biologic or targeted synthetic DMARD; assess for treat-to-target
Interpretation bands for the DAS28-CRP. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxychloroquine · Aminoquinoline — Malaria Prophylaxis / SLE / Rheumatoid Arthritis
- Methotrexate (Low-dose) · DMARD (Disease-Modifying Antirheumatic Drug) / Immunosuppressant
- Adalimumab · Biologic DMARD (TNF-alpha inhibitor, monoclonal antibody)
- Tocilizumab · Biologic DMARD (IL-6 receptor antagonist)
- Rituximab (Rheumatology) · Biologic DMARD — Anti-CD20
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.